Latest posts

• 2026.07.30

  Phase I Clinical Trial Results of ⁶⁴Cu-ATSM Radioligand Therapy for Recurrent Malignant Brain Tumors Published in ESMO Open, a Peer-Reviewed Journal

• 2026.05.14

  LinqMed Selected for the UK Program Following the Pitch Contest at the Nakanoshima Qross Innovation Challenge

• 2025.12.24

  Demonstration of the Efficacy of Hypoxia-Targeted Local Radiotherapy for Malignant Brain Tumors

• 2025.11.18

  LinqMed Announces Completion of the Chiba Factory

• 2025.05.12

  LinqMed Announces the Final Close of Series B

• 2025.04.09

  LinqMed Announces the Second and Third Closes of Series B

• 2025.03.05

  LinqMed Wins Grand Prize at Go Global! ENGLISH Pitch Competition 2024 FINAL PITCH @ Blockbuster TOKYO

• 2025.01.10

  LinqMed Announces 1st Close of Series B

• 2024.08.23

  LinqMed received the “University Venture Award Special Prize” at the University Venture Award 2024

• 2024.06.25

  Confirmation of Safety and Efficacy of Japan-Originated 64Cu-ATSM in Recurrent or Refractory Malignant Brain Tumors Phase III Trial Initiated Toward Regulatory Approval